Publications
229
Citations
5,236
Est. group size
—
Recurring co-author estimate
Active years
43
Publishing since 1983
- Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies
Dermatology and Therapy · 2025
- Lebrikizumab Improves Atopic Dermatitis and Quality of Life in Patients With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab: Results From the ADapt Trial
SKIN The Journal of Cutaneous Medicine · 2025
- Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks
American Journal of Clinical Dermatology · 2025
- Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo
Dermatology and Therapy · 2025
- A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel
Journal of Drugs in Dermatology · 2025
- Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa
JAMA Dermatology · 2025
- Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study
British Journal of Dermatology · 2025
- Corrigendum to “Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study” [eClinicalMedicine 73(2024) 102655]
EClinicalMedicine · 2025
- Measles resurgence: What every dermatologist should know
Journal of the American Academy of Dermatology · 2025
- Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials
Dermatology · 2025
- 63728 Increased risk of herpes infections in patients with atopic dermatitis who started a JAK-inhibitor vs. Th2 cytokine-inhibitor: a propensity-score matched claims data study
Journal of the American Academy of Dermatology · 2025
- REZPEGALDESLEUKIN, NOVEL TREG-INDUCING THERAPY, DEMONSTRATES EFFICACY IN ATOPIC DERMATITIS AND ASTHMA IN PHASE 2B TRIAL
Annals of Allergy Asthma & Immunology · 2025
- International multicenter case series of gestational dupilumab exposure in the treatment of atopic dermatitis: Maternal complications and fetal outcomes
Journal of the American Academy of Dermatology · 2025
- Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publication
Therapeutic Advances in Chronic Disease · 2025
- Tapinarof Cream 1% Once Daily: Consistent Efficacy Across All Body Regions, Including Head And Neck, In Adults And Children Down To 2 Years Of Age With Atopic Dermatitis
Journal of Allergy and Clinical Immunology · 2025
- Journal of the American Academy of Dermatology×58
- British Journal of Dermatology×25
- Journal of Investigative Dermatology×10
- Journal of the European Academy of Dermatology and Venereology×9
- Dermatology and Therapy×9
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile